The Immune Atlas identifies immune signatures in MM, enhancing outcome prediction and guiding personalized therapies by ...

Large BIDMC-led study maps immune cells in myeloma tumors, improving risk prediction beyond genetics and helping identify ...

In this secondary analysis of the ECOG-ACRIN E2906 study, researchers assessed vulnerabilities of AML patients aged 60 years or older and their affect on survival outcomes.

Researchers evaluated sex differences in clinical features and chromosomal abnormalities in 850 patients with newly diagnosed multiple myeloma.

So in general, really blinatumomab was very well tolerated. There were some more cytopenias in some of the patients with ...

The combination therapy, referred to as DAGO+m, yielded a 91% overall response rate and a promising 2-year overall survival ...

According to the IAEA’s latest bulletin, the work focused on clinical applications of biodosimetry — the use of biological ...

RYTELO® (imetelstat) net product revenue expected in the range of $220 to $240 million2026 total operating expenses expected in the range of ...

PRESS RELEASE AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA ...

An IAEA research project involving 27 countries has strengthened global understanding of how exposure to ionizing radiation affects human health. The project focused on the clinical applications of ...

Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one ...